Kadcyla (ado-trastuzumab emtansine) / ImmunoGen, AbbVie, Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

97 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kadcyla (ado-trastuzumab emtansine) / Roche
NCT00509769: A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Checkmark Pooled P2 data
Dec 2011 - Dec 2011: Pooled P2 data
Completed
2
112
US
Trastuzumab emtansine [Kadcyla], trastuzumab-DM1, trastuzumab-MCC-DM1, T-DM1
Genentech, Inc.
Metastatic Breast Cancer
01/09
06/09
NCT00679211: A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Checkmark P2 data
Jun 2012 - Jun 2012: P2 data
Checkmark Pooled P2 data
Dec 2011 - Dec 2011: Pooled P2 data
Completed
2
110
NA
Trastuzumab emtansine [Kadcyla], Trastuzumab-MCC-DM1, T-DM1
Genentech, Inc.
Metastatic Breast Cancer
09/09
04/11
NCT00679341 / 2008-002819-40: A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Checkmark
Jun 2013 - Jun 2013: 
Checkmark P2 data - ESMO
Sep 2012 - Sep 2012: P2 data - ESMO
Checkmark Pooled P2 data
More
Completed
2
137
US
Trastuzumab emtansine [Kadcyla], trastuzumab-DM1, trastuzumab-MCC-DM1, T-DM1, Trastuzumab, Herceptin, Docetaxel, Taxotere
Hoffmann-La Roche
Breast Cancer
11/10
05/12
NCT00943670: Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Completed
2
51
US
pertuzumab, PERJETA™, Trastuzumab emtansine [Kadcyla], trastuzumab-MCC-DM1, T-DM1
Genentech, Inc.
Metastatic Breast Cancer
12/10
08/11
2008-002819-40: A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease

Completed
2
120
Europe, RoW
Trastuzumab-MCC-DM1, T-DM1, RO05304020, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Herceptin 150 mg Powder for concentrate for solution for infusion, TAXOTERE 80 mg concentrate and solvent for solution for infusion
F. Hoffmann-La Roche Ltd, F Hoffmann-La Roche Ltd, ROCHE
HER2-positive metastatic breast cancer
 
 
NCT01196052 / 2010-019752-50: A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Checkmark P2 data
Jun 2012 - Jun 2012: P2 data
Completed
2
153
US, Europe, RoW
Trastuzumab emtansine, T-DM1
Hoffmann-La Roche
Breast Cancer
06/13
06/13
2014-000793-19: Early phase Clinical trial, Randomized Study of T DM1 versus T DM1 plus docetaxel in first line treatment for locally advanced or metastatic HER2+ breast cancer. Ensayo clínico de fase temprana, aleatorizado, de T-DM1 frente a T-DM1 e inducción corta con docetaxel en primera línea de tratamiento del cáncer de mama localmente avanzado o metastásico HER2+.

Ongoing
2
236
Europe
Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Kadcyla
SOLTI, SOLTI
Progressive or recurrent, locally advanced unresectable or metastatic HER2+ breast carcinoma in patients who have not received previous chemotherapy for the advanced disease. Carcinoma de mama HER2+, localmente avanzado no operable o metastásico, en pacientes que no han recibido quimioterapia previa para la enfermedad avanzada., Progressive or recurrent, locally advanced unresectable or metastatic HER2+ breast carcinoma in patients who have not received previous chemotherapy for the advanced disease. Carcinoma de mama HER2+, localmente avanzado no operable o metastásico, en pacientes que no han recibido quimioterapia previa para la enfermedad avanzada., Diseases [C] - Cancer [C04]
 
 
2014-000808-10: PREDIX HER2 - preoperative treatment of HER2 positive breast cancer

Ongoing
2
200
Europe
Herceptin, Perjeta, Kadcyla, docetaxel, Solution for injection, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Concentrate and solvent for concentrate for solution for infusion, Herceptin, Perjeta, Kadcyla
Karolinska University Hospital, Dept. of Oncology, Karolinska University Hospital
Primary breast cancer, Newly diagnosed preoperative breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT01745965: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.

Completed
2
380
Europe
T-DM1, Trastuzumab, Herceptin
West German Study Group, Roche Pharma AG
Breast Cancer
02/15
01/25
2010-019752-50: “ESTUDIO FASE II MULTINACIONAL, MULTICÉNTRICO,PARA EVALUAR LA SEGURIDAD CLÍNICA Y VIABILIDAD DE LA ADMINISTRACIÓN DE T-DM1 DE FORMA SECUENCIAL CON UN RÉGIMEN DE QUIMIOTERAPIA BASADO EN ANTRACICLINAS, PARA EL TRATAMIENTO ADYUVANTE O NEOADYUVANTE DE PACIENTES CON CÁNCER DE MAMA HER2 POSITIVO PRECOZ”A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1 sequentially with anthracyline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients with early stage HER2-positive breast cancer.

 
2
24
Europe
trastuzumab-MCC-DM1 (TDM-1), RO5304020/F02, TAXOTERE 20 mg/1 ml concentrado para solución para perfusión, MYOCET 50 mg polvo y premezclas concentrado para dispersión liposómica para perfusión, EPIRUBICINA MAYNE 2 mg/ml solución inyectable, FLUOROURACILO FERRER FARMA 50 mg/ml solución inyectable, GENOXAL 1 g Inyectable, TAXOTERE 80 mg/4 ml concentrado para solución para perfusión, HERCEPTIN 150 mg polvo para concentrado para solución para perfusión, TAXOTERE 20 mg/1 ml concentrado para solución para perfusión, MYOCET 50 mg polvo y premezclas concentrado para dispersión liposómica para perfusión, EPIRUBICINA MAYNE 2 mg/ml solución inyectable, FLUOROURACILO FERRER FARMA 50 mg/ml solución inyectable, GENOXAL 1 g Inyectable, TAXOTERE 80 mg/4 ml concentrado para solución para perfusión, HERCEPTIN 150 mg polvo para concentrado para solución para perfusión
F. Hoffmann-La Roche Ltd
Neoadyuvante o adyuvante en cáncer de mamaTreatment of HER2 positive adjuvant or neoadjuvant therapy
 
06/13
NCT02289833 / 2014-001237-83: A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Checkmark In HER2+ve 2L NSCLC at ASCO 2017
Jun 2017 - Jun 2017: In HER2+ve 2L NSCLC at ASCO 2017
Completed
2
49
Europe, US, RoW
Trastuzumab Emtansine, Kadcyla, T-DM1
Hoffmann-La Roche
Non-Small Cell Lung Cancer
10/16
08/18
EORTC-75111-10114, NCT01597414 / 2011-006342-32: Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

Completed
2
80
Europe
Pertuzumab + trastuzumab, Pertuzumab + trastuzumab + metronomic chemotherapy
European Organisation for Research and Treatment of Cancer - EORTC, Hoffmann-La Roche
Elderly Metastatic Breast Cancer Population
03/17
11/22
TRAXHER2, NCT01702558 / 2012-001547-46: A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Terminated
2
182
Europe, Canada, RoW
Capecitabine, Xeloda, Trastuzumab emtansine (T-DM1), Kadcyla,, RO5304020
Hoffmann-La Roche
Breast Cancer, Gastric Cancer
05/17
05/17
KATE2, NCT02924883 / 2015-004189-27: A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Completed
2
202
Europe, Canada, US, RoW
Atezolizumab, Tecentriq, RO5541267, MPDL3280A, Trastuzumab emtansine, Kadcyla®, T-DM1, RO5304020, Placebo
Hoffmann-La Roche
Metastatic Breast Cancer
12/17
02/20
PERNETTA, NCT01835236 / 2012-002556-17: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Completed
2
208
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Paclitaxel, Taxol, Vinorelbine, Navelbine, T-DM1, Trastuzumab emtansine
Swiss Group for Clinical Cancer Research
Metastatic Breast Cancer
01/18
05/20
NCT01975142: Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Completed
2
155
Europe
Trastuzumab - Emtansine
Institut Curie
Metastatic Breast Cancer, HER2 Negative Primary Tumor
02/18
01/19
KAMELEON, NCT02999672 / 2015-001377-40: A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors

Completed
2
20
Europe
Trastuzumab Emtansine, Kadcyla
Hoffmann-La Roche
Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
04/18
04/18
NCT02326974: T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Active, not recruiting
2
164
US
T-DM1, Kadcyla, Pertuzumab, Perjeta, Excision of tumor/mastectomy
Dana-Farber Cancer Institute, Genentech, Inc.
HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
06/18
01/28
2014-005341-44: Tumor profiling

Completed
2
64
Europe
Vargatef, EMEA/H/C/002569, Tablet, Powder for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Powder for injection, Solution for infusion, , Capsule, Suspension for injection, Powder for concentrate for solution for injection/infusion, Concentrate for solution for injection/infusion, Capsule, soft, Concentrate for solution for injection, Concentrate and solvent for solution for injection/infusion, Powder for solution for infusion, Implant, Kit for radiopharmaceutical preparation, Capsule, hard, Solution for injection/infusion, Powder and solvent for solution for injection, Solution for injection in pre-filled syringe, Concentrate and solvent for solution for infusion, Powder for solution for injection, Powder and solvent for solution for injection in pre-filled syringe, Concentrate and solvent for concentrate for solution for infusion, Solution for injection, Zytiga, Kadcyla, Giotrif, Arimidex, Trisenox, Erwinase, Inlyta, Vidaza, Levact, Avastin, Bleomycin, Velcade, Bosulif, Adcetris, Jevtana, Xeloda, Carboplatin, Erbitux, Leukeran, Cisplatin, Evoltra, Xalkori, Endoxan powder and capsule, Alexan and Cytarabin, Tafinlar, DepoCyte, Dacarbazin Lipomed, Sprycel, Daunoblastin, Dacogen, Firmagon, Docetaxel and Taxotere, Myocet, Caelyx, Epirubicin and Farmorubicin, Xtandi, Halaven, Tarceva, Etoposid concentrate and Vepesid capsule, Afinitor, Exemestan and Aromasin, Faslodex, Neoflubin, 5-Fluorouracil "Ebewe", Iressa, Gemzar, Zoladex, Zevalin, Imbruvica, Holoxan, Glivec, IntronA, Yervoy, Irinotecan, Tyverb, Revlimid, Femara, Calciumfolinat, Eligard Depot and Trenantone, Puri-Nethol and Xaluprine suspension, Methotrexat "Lederle" and Ebetrexat, Methotrexat and Ebetrexat, Metoject PEN and Ebetrexat and Methotrexat, Mitomycin C, Tasigna, Gazyvaro, Arzerra, Eloxatin and Ebeoxal and Oxaliplatin, Abraxane and Ebetaxel and Paclitaxel, Vectibix, Votrient, PegIntron and ViraferonPeg, PegIntron and ViraferonPeg injector, Alimta, Perjeta, Imnovid, Iclusig, Fortecortin and Aprednislon, Stivarga, MabThera, Jakavi, Nexavar, Sutent, Nolvadex, Temozolomide SUN, Torisel, Thalidomide, Hycamitin, Fareston, Mekinist, Herceptin and Kadcyla, Zelboraf, Velbe, Oncovin and Vincristin, Navelbine and Eberelbin, Zaltrap, Vargatef
Medical University of Graz, Medical University of Graz
Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected., Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established., Diseases [C] - Cancer [C04]
 
 
2016-004398-41: Multicentre, non-randomised, open-label, single agent phase II study to determine the clinical benefit of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer patients with brain metastasis

Terminated
2
110
Europe
Kadcycla, Concentrate for solution for infusion, KADCYCLA
Institut Jules Bordet, F- Hoffmann-La-Roche
Metastatic HER2-positive breast cancer with brain metastasis, Metastatic HER2-positive breast cancer with brain metastasis, Diseases [C] - Cancer [C04]
 
 
KIARA, NCT03203616: Kadcyla In pAtients With bRAin Metastasis

Withdrawn
2
0
NA
KADCYLA 160 MG Injection, T-DM1, trastuzumab emtansine
Jules Bordet Institute
Metastatic HER2-positive Breast Cancer With Brain Metastasis
08/18
08/18
HERACLES RESCUE, NCT03225937 / 2012-002128-33: Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer

Unknown status
2
54
Europe
Trastuzumab, Lapatinib, Pertuzumab, trastuzumab-emtansine
Fondazione del Piemonte per l'Oncologia
Metastatic Colorectal Cancer
12/18
06/19
NCT02414646: Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer

Active, not recruiting
2
200
US
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-TRASTUZUMAB EMTANSINE, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Estrogen Receptor Status, HER2 Positive Breast Carcinoma, Progesterone Receptor Status, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
12/18
03/22
TEAL, NCT02073487: Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Completed
2
32
US
T-DM1, trastuzumab emtansine, Kadcyla, Trastuzumab, Herceptin, Lapatinib, tykerb, Abraxane, nab-paclitaxel, Paclitaxel, Taxol, Pertuzumab, Perjeta
The Methodist Hospital Research Institute, Celgene Corporation, Novartis
Breast Cancer
01/19
01/19
MATCH-Subprotocol Q, NCT04439110: Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes

Active, not recruiting
2
38
US
Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
03/19
03/26
DESTINY-Breast01, NCT03248492 / 2016-004986-18: A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Checkmark Updated OS data from P2 DESTINY-Breast01 trial for HER2 positive metastatic breast cancer at ESMO
Jul 2021 - Jul 2021: Updated OS data from P2 DESTINY-Breast01 trial for HER2 positive metastatic breast cancer at ESMO
Checkmark Market entry in Europe for HER positive breast cancer
Apr 2021 - Apr 2021: Market entry in Europe for HER positive breast cancer
Checkmark Authorised in the UK for HER2+ve unresectable/metastatic 3L breast cancer
More
Terminated
2
253
Europe, Canada, Japan, US, RoW
DS-8201a, Experimental product
Daiichi Sankyo, AstraZeneca, Daiichi Sankyo Co., Ltd.
Breast Cancer
03/19
05/24
NATURE, NCT02725541: Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

Withdrawn
2
0
US
Trastuzumab emtansine, ado-trastuzumab emtansine; T-DM1; KADCYCLA
Jenny C. Chang, MD, Genentech, Inc., The Methodist Hospital Research Institute
Breast Cancer
04/19
05/19
SAFE-HEaRt, NCT01904903: Cardiac Safety Study in Patients With HER2 + Breast Cancer

Completed
2
31
US
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Ado Trastuzumab Emtansine, Kadcyla
Medstar Health Research Institute, Genentech, Inc.
HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction
06/19
06/20
RESCUE, NCT03418558 / 2015-003275-30: Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.

Unknown status
2
13
Europe
Trastuzumab emtansine
Fondazione del Piemonte per l'Oncologia, Roche S.p.A., AIRC
Metastatic Colorectal Cancer
06/19
06/19
ATEMPT, NCT01853748: T-DM1 vs Paclitaxel/Trastuzumab for Breast ( Trial)

Checkmark Presentation of data from ATEMPT trial for HER2-positive breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from ATEMPT trial for HER2-positive breast cancer at SABCS 2022
Active, not recruiting
2
512
US
Trastuzumab, Paclitaxel, Trastuzumab emtansine, T-DM1
Dana-Farber Cancer Institute
Breast Cancer
08/19
12/25
2019-002181-12: OPTIMAL THERAPY FOR HER2 POSITIVE METASTATIC BREAST CANCER PATIENTS TERAPIA OTTIMALE PER LE PAZIENTI AFFETTE DA TUMORE DELLA MAMMELLA MESTASTATICO HER2 POSITIVO

Terminated
2
101
Europe
KADCYLA, Capecitabina, TYVERB, [Trastuzumab emtansine], [Capecitabina], [LAPATINIB], Powder and solvent for solution for infusion, Film-coated tablet, KADCYLA, TYVERB - 250 MG COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 70 COMPRESSE
ISTITUTI FISIOTERAPICI OSPITALIERI, Ministero della Salute - Ricerca Finalizzata GR 2018-12367431
HER2 POSITIVE METASTATIC BREAST CANCER CARCINOMA MAMMARIO METASTATICO HER2 POSITIVO, HER2 POSITIVE METASTATIC BREAST CANCER CARCINOMA MAMMARIO METASTATICO HER2 POSITIVO, Diseases [C] - Cancer [C04]
 
 
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
2019-004771-40: ProTargetA Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling

Not yet recruiting
2
300
Europe
Zejula, Capsule, hard, Concentrate and solvent for solution for infusion, Tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Alcensa, Tecentriq, Cotellic, Zelboraf, Herceptin, Perjeta, Kadcyla, Erivedge, Bavencio, Inlyta, Zejula, pemazyre, Retsevmo
Rigshospitalet, Roche, Pfizer
Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function. Patienter med fremskreden og/eller metastatisk solid tumor, som har oplevet progression under standardbehandling, eller som er intolerante over for standardbehandling, Patients with advanced cancer without curative therapeutic options Patienter med fremskreden kræft uden mulighed for kurativ behandling, Diseases [C] - Cancer [C04]
 
 
2019-005019-18: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2positive breast cancer with high HER2 addiction and a complete response following standard anti- HER2-based neoadjuvant therapy (ELPIS trial) Omisión de cirugía y disección de ganglios linfáticos centinela en cáncer de mama HER2 positivo de bajo riesgo clínico con tumor de alta adicción a HER2 y una respuesta completa después de la terapia neoadyuvante basada en anti-HER2 estándar (ensayo ELPIS)

Ongoing
2
27
Europe
Trastuzumab/pertuzumab FDC, Paclitaxel, TRASTUZUMAB EMTANSINE, cyclophosphamide, epirubicin, Paclitaxel, TDM-1, Infusion, Powder for solution for injection/infusion, Solution for injection/infusion, Phesgo, Paclitaxel, TRASTUZUMAB EMTANSINE, Epirubicin, Doxorubicin
Fundació Clínic per a la Recerca Biomèdica, Roche
Breast cancer Cáncer de mama, Breast cancer Cáncer de mama, Diseases [C] - Cancer [C04]
 
 
TRAEMOS, NCT03784599: T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

Terminated
2
28
Europe
Trastuzumab emtansine, Osimertinib
The Netherlands Cancer Institute, AstraZeneca, Roche Pharma AG
Carcinoma, Non-Small-Cell Lung
05/21
05/21
PREDIX II HER2, NCT03894007: Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

Terminated
2
6
Europe
Docetaxel, Carboplatin, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Epirubicin, Cyclophosphamide, Atezolizumab, Tecentriq, Trastuzumab emtansine, Kadcyla, Paclitaxel
Renske Altena
Early-stage Breast Cancer, HER2-positive Breast Cancer
06/21
06/21
Neo-peaks, UMIN000014649: A randomized, multicenter, phase II trial comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer( study)

Completed
2
200
Japan
tamoxifen - Generic mfg., letrozole - Generic mfg., 5-fluorouracil - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg., Perjeta (pertuzumab) - Roche, docetaxel - Generic mfg., carboplatin - Generic mfg., Herceptin (trastuzumab) - Roche, Kadcyla (ado-trastuzumab emtansine) - Roche
Japan Breast Cancer Research Group(JBCRG), Chugai Pharmaceutical CO.,LTD
operable HER2-positive primary breast cancer
 
 
2018-004457-24: PREDIX II HER2 - improving preoperative treatment of HER2 amplified breast cancer

Terminated
2
190
Europe
Herceptin, Tecentriq, Kadcyla, Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide, Pertuzumab, Paklitaxel, Solution for injection, Solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Herceptin, Tecentriq, Kadcyla
Karolinska University Hospital, Karolinska University Hospital
Primary breast cancer, Newly diagnosed HER2 amplified breast cancer, Diseases [C] - Cancer [C04]
 
 
2020-005276-35: ARTesunate in combInation with standard-of-care T-DM1 as Second-line Treatment in patients with advanced HER2-positive breast cancer progressIng on trastuzumab-pertuzumab Chemotherapy: the ARTISTIC study Artesunato in combinazione con T-DM1 come seconda linea di trattamento in pazienti con tumore mammario HER2-positivo avanzato in progressione a biochemioterapia contenente trastuzumab-pertuzumab: lo studio ARTISTIC

Not yet recruiting
2
25
Europe
Co-arinate, [Artestunato], Tablet, Co-Arinate
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Roche S.p.A.
patient PFS in metastatic HER2+ breast cancer undergoing tumor progression during first-line taxane-trastuzumab-pertuzumab biochemotherapy or trastuzumab-pertuzumab maintenance, and candidate to receive second-line T-DM1 pazienti con tumore mammario HER2+ in fase avanzata e candidati a trattamento di seconda linea con T-DM1 dopo progressione a chemioterapia di prima linea contenente Trastuzumab-Pertuzumab o terapia di mantenimento con Trastuzumab-Pertuzumab., metastatic HER2+ breast cancer tumore mammario HER2+, Diseases [C] - Cancer [C04]
 
 
ACCRU-BR-1801, NCT04351230: T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Withdrawn
2
0
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
02/22
02/22
2021-001246-36: A clinical research study to test different doses of a study drug (ARX788), to see which dose is safest and its effectiveness(shrinks tumor size) in patients with advanced cancer. Estudio de investigación clínica para probar diferentes dosis del fármaco del estudio (ARX788), para ver qué dosis es la más segura y su efectividad (redución tamaño del tumor) en pacientes con cáncer avanzado.

Not yet recruiting
2
210
Europe
ARX788, ARX788, Solution for infusion
Ambrx, Inc., Ambrx, Inc.
Metastatic Breast Cancer Resistant or Refractory Cáncer de mama metastásico resistente o refractario, Advanced Cancer that is metastasic Cáncer avanzado metastásico, Diseases [C] - Cancer [C04]
 
 
NCT03530696: T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

Completed
2
55
US
Palbociclib, Ibrance, T-DM1, Kadcyla
University of Arizona, Pfizer
HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage, Recurrent Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
12/22
12/22
NCT04398914: Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Active, not recruiting
2
216
RoW
Pyrotinib, Trastuzumab, Pertuzumab, Nab-paclitaxel, EC chemotherapy, Physician's choice, T-DM1, Surgery
Shanghai Jiao Tong University School of Medicine, Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer Invasive
12/22
12/27
TBCRC 022, NCT01494662: HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Hourglass Jan 2022 - Jun 2022 : Data from trial in combination with neratinib for HER2-positive breast cancer with brain metastases
Hourglass Jul 2021 - Dec 2021 : Data from cohort 4 of P2 trial in combination with kadcyla for HER2-positive breast cancer
Checkmark Pooled data from NALA, NEfERT-T and TBCRC 022 trials for HER2-positive breast cancer at SABCS 2019
Dec 2019 - Dec 2019: Pooled data from NALA, NEfERT-T and TBCRC 022 trials for HER2-positive breast cancer at SABCS 2019
Checkmark In HER2+ metastatic breast cancer with brain metastases
More
Active, not recruiting
2
140
US
HKI-272, Neratinib, Surgical Resection, Biopsy, Capecitabine, Xeloda, Ado-Trastuzumab Emtansine, T-DM1
Dana-Farber Cancer Institute, Translational Breast Cancer Research Consortium, Puma Biotechnology, Inc.
Breast Cancer
02/23
12/25
2020-002918-41: De-Escalation of neoadjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade

Completed
2
1065
Europe
FDC pertuzumab and trastuzumab with recombinant human hyaluronidase (rHuPH20), Paclitaxel, Docetaxel, trastuzumab emtansine, RO7198574, Solution for injection, Concentrate for solution for infusion, Concentrate and solvent for concentrate for solution for infusion, Powder for concentrate for solution for infusion, PHESGO, Kadcycla
Institut Jules Bordet, F. Hoffmann-La-Roche
HER2-positive, estrogen receptor (ER)-negative/progesterone receptor (PR)-negative, node-negative early breast cancer, Early breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT06481956: T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Enrolling by invitation
2
40
RoW
Ribociclib Oral Tablet
Zheng Yabing
HER2-positive Advanced Breast Cancer
01/27
10/27
PATRICIA, NCT02448420 / 2014-005006-38: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

Completed
2
73
Europe
Palbociclib, Ibrance, Trastuzumab, Herceptin, Endocrine therapy, ET, Chemotherapy, CT, Antibody-Drug Conjugates, Trastuzumab emtansine (TDM-1)
SOLTI Breast Cancer Research Group
Metastatic Breast Cancer
09/23
11/23
MyTACTIC, NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
2
252
US
Entrectinib, Rozlytrek™, RG6268, RO7102122, Inavolisib, GDC-0077, RG6114, RO7113755, Alectinib, Alecensa®, RG7853, RO5424802, Ipatasertib, GDC-0068, RG7440, RO5532961, Atezolizumab, Tecentriq®, RG7446, RO5541267, Trastuzumab Emtansine, Kadcyla®, RG3502, RO5304020, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574, Tucatinib, Tukysa™, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, RG6058, RO7092284, MTIG7192A, Pralsetinib, GAVRETO™, RG6396, RO7499790
Genentech, Inc.
Advanced Unresectable or Metastatic Solid Malignancy
12/23
02/24
HER2BAT, NCT04158947: A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone

Recruiting
2
130
RoW
Afatinib, BIBW 2992, T-DM1, Trastuzumab emtansine
xuexin he
HER2-positive Breast Cancer, Brain Metastases
12/23
03/24
NCT04769050: Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Recruiting
2
50
RoW
Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.
Fudan University
Breast Cancer
12/23
12/23
SCHOLAR-2, NCT04680442: Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Recruiting
2
130
Canada, RoW
Trastuzumab, Herceptin, Herzuma, Ogivri, Trazimera, Kanjinti, Pertuzumab, Perjeta, Trastuzumab emtansine, Kadcyla,
Population Health Research Institute
Breast Cancer, Heart Failure
12/25
06/26
ZEPHIR, NCT01565200 / 2011-005437-39: HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
90
Europe
T-DM1, Trastuzumab-DM1, 89Zr-trastuzumab, Zirconium 89 labelled trastuzumab
Jules Bordet Institute, Roche Pharma AG
HER-2 Positive Breast Cancer
07/17
12/22
NCT02675829: Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Active, not recruiting
2
131
US
ado-trastuzumab emtansine
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Solid Tumor Cancers, Lung Cancer, Bladder Cancer, Urinary Tract Cancers
02/26
02/26
BRIDGET, NCT05323955: Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

Active, not recruiting
2
48
US
Trastuzumab, Herceptin, Trastuzumab Emtansine (T-DM1), Pertuzumab, Perjeta, Tucatinib, Tukysa
Carey Anders, M.D., Pfizer
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
04/26
07/26
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/29
04/30
TBCRC065, NCT06439693: The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Recruiting
2
72
US
Nab-Paclitaxel, Abraxane, ABI-007, Albumin-bound paclitaxel, Paclitaxel, Taxol, Docetaxel, Taxotere, Phesgo, pertuzumab plus trastuzumab plus hyaluronidase-zzxf, RG6264, RO7198574, T-DM1, ado-trastuzumab emtansine, Kadcyla, Pertuzumab, Trastuzumab Deruxtecan, Enhertu, fam-trastuzumab deruxtecan-nxki, T-DXd, DS-8201a, Trastuzumab Subcutaneous Subcutaneous, Herceptin Hylecta, Trastuzumab and hyaluronidase-oysk, Tucatinib, Trastuzumab
Dana-Farber Cancer Institute, Translational Breast Cancer Research Consortium, Johns Hopkins University
Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
03/30
03/33
NCT05560308: Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

Not yet recruiting
2
50
NA
Trastuzumab Emtansine for Injection, Pyrotinib Maleate Tablets
Tianjin Medical University Cancer Institute and Hospital
HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
08/24
08/25
MoST Addendum 8, ACTRN12619001265167: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 8 substudy 19: T-DM1

Completed
2
64
 
The University of Sydney, Office for Health and Medical Research, Australian Genomic Cancer Medicine Centre (AGCMC)
Cancer
 
 
DARWIN II, NCT02314481: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruiting
2
50
Europe
MPDL3280A, Atezolizumab, Vemurafenib, Zelboraf, Alectinib, Alecensa, Trastuzumab emtansine, T-DM1, Kadcyla
University College, London, Hoffmann-La Roche
Non-small Cell Lung Cancer
05/26
05/26
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
ACCRU-BR-1701, NCT04197687: TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Recruiting
2
480
US
Multi-epitope HER2 Peptide Vaccine TPIV100, HER2/Neu Peptide Vaccine TPIV100, Peptide Vaccine TPIV100, TPIV 100, TPIV-100, TPIV100, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Placebo Administration, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
01/25
01/25
NCT04620187: Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Recruiting
2
55
US
Ado-trastuzumab (T) emtansine (T-DM1), Kadcyla, Standard of Care Radiotherapy, Radiation, Standard of Care Chemotherapy, Cisplatin, carboplatin
Dana-Farber Cancer Institute, Genentech, Inc.
Salivary Gland Cancer, HER2 Gene Mutation
02/26
02/27
NCT06125834: Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Recruiting
2
36
RoW
Trastuzumab Emtansine (T-DM1)
The First Affiliated Hospital with Nanjing Medical University
Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine
04/25
05/26
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
11/26
05/28
NCT04419181: Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Withdrawn
2
20
US
Docetaxel, Taxotere, Carboplatin, Paraplatin, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Trastuzumab emtansine, TDM1
University of Rochester
HER2-positive Breast Cancer
06/26
06/27
KAN-HER2 MRD, NCT05388149: Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Recruiting
2
15
Canada
Neratinib, NERLYNX
University Health Network, Toronto
Breast Cancer, HER2-positive Breast Cancer
07/26
07/26
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
03/27
03/28
ZEPHIR-02, NCT06595563: HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

Not yet recruiting
2
87
NA
Trastuzumab emtansine, T-DM1
Jules Bordet Institute, Hoffmann-La Roche
HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer
03/28
09/29
HQBP-IIT-2025, NCT07257809: Herombopag Treated T-DM1 Induced Platelet Reduction

Recruiting
2
56
RoW
Herombopag Olamine Tablets
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thrombocytopenia
09/26
09/27
NCI-MATCH, NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Checkmark Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Jan 2023 - Jan 2023: Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Checkmark Approved in combination with for Mekinist for BRAF V600E solid tumors
Jun 2022 - Jun 2022: Approved in combination with for Mekinist for BRAF V600E solid tumors
Checkmark Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
More
Active, not recruiting
2
6452
US, RoW
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775, Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography, Copanlisib, BAY 80 6946, BAY 80-6946, BAY 806946, BAY-80-6946, BAY806946, PI3K Inhibitor BAY 80-6946, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Defactinib, PF-04554878, VS-6063, Defactinib Hydrochloride, Echocardiography Test, EC, Echocardiography, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Fexagratinib, ABSK-091, ABSK091, AZD4547, FGFR Inhibitor AZD4547, KB-74810, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Laboratory Biomarker Analysis, Larotrectinib, ARRY 470, LOXO 101, LOXO-101, LOXO101, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Pertuzumab-dpzb, Poherdy, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771, Radiologic Examination, Radiologic Evaluation, Radiologic Exam, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Sunitinib Malate, SU 011248, SU 11248, SU-011248, SU-11248, SU011248, SU11248, sunitinib, Sutent, Taselisib, GDC-0032, RO5537381, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Ulixertinib, BVD-523, VRT752271, Vismodegib, Erivedge, GDC 0449, GDC-0449, GDC0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
12/26
12/26
NCT06348134: Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Not yet recruiting
2
74
US, RoW
Trastuzumab emtansine, Kadcyla, T-DMI, Pertuzumab Injection, Perjeta, Docetaxel, Taxotere, Docefrez, Tamoxifen, Soltamox, Letrozole, Goserelin, Zoladex
University of Chicago
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer
07/34
07/36
ATOP TRIAL, NCT03587740: T-DM1 in HER2 Positive Breast Cancer

Active, not recruiting
2
82
US
T-DM1, Kadcyla
Dana-Farber Cancer Institute, Susan G. Komen Breast Cancer Foundation, Gateway for Cancer Research
Breast Cancer
08/26
08/29
EA1181, NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Active, not recruiting
2
2175
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
TUCATEMEB, NCT05673928: A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain

Recruiting
2
30
US
Trastuzumab emtansine, T-DM1, Trastuzumab-MCC-DM1, Kadcyla, ado-trastuzumab emtansine, Tucatinib, ARRY-380, ONT-380
M.D. Anderson Cancer Center, Genentech, Inc., Seagen Inc.
Metastatic Solid Tumor, Brain Metastases
03/27
03/29
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Terminated
2
139
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
11/24
11/24
BOUQUET, NCT04931342 / 2020-004936-72: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruiting
2
176
Europe, Canada, US, RoW
Ipatasertib, RO5532961, Cobimetinib, RO5514041, Trastuzumab Emtansine, RO5304020, Atezolizumab, RO5541267, Tecentriq, Bevacizumab, RO4876646, Avastin, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Hoffmann-La Roche, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Ovarian Cancer
02/28
05/28
NRG-HN010, NCT05408845: Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Recruiting
2
146
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Echocardiography Test, EC, Echocardiography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
NRG Oncology, National Cancer Institute (NCI)
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
07/28
07/28
NCT00781612 / 2010-021067-32: A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Active, not recruiting
2
720
Europe, Canada, Japan, US, RoW
Docetaxel, Paclitaxel, Pertuzumab, Perjeta, Trastuzumab, Herceptin, Trastuzumab Emtansine, Kadcyla; T-DM1, Atezolizumab, Tecentriq
Genentech, Inc., Hoffmann-La Roche
Neoplasm Metastasis
09/29
04/30
ChiCTR2500108585: An exploratory study of neoadjuvant therapy with toripalimab combined with Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection and nab-paclitaxel in patients with HER2-positive stage II–III breast cancer.

Recruiting
2
112
 
toripalimab , Pertuzumab and Trastuzumab Injection (Subcutaneous Injection), nab-paclitaxel;T-DM1;
The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University, Optional Project (Self-Funded)
HER2-positive, stage II to III breast cancer
 
 
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jul 2025 - Dec 2025 : Top-line P1b data from ALX148 and Enhertu combo for breast cancer
Hourglass Dec 2025 - Dec 2025 : Data of vepdegestrant mono or in combo with letrozole or abema for neoadj stage 2/3 HR+ HER2- BC
Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
TAPISTRY, NCT04589845 / 2020-001847-16: Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You () Platform Study

Recruiting
2
920
Europe, Canada, Japan, US, RoW
Entrectinib, Rozlytrek, Alectinib, Alecensa, Atezolizumab, Tecentriq, Ipatasertib, Trastuzumab emtansine, Kadcyla, Inavolisib, GDC-0077, Belvarafenib, Pralsetinib, Gavreto (US), Divarasib, GDC-6036, Camonsertib
Hoffmann-La Roche
Solid Tumors
09/32
09/32
NCT00875979 / 2008-008276-14: A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Checkmark In combination with pertuzumab in pts with HER2+ve, locally adv/mets BC
Apr 2014 - Apr 2014: In combination with pertuzumab in pts with HER2+ve, locally adv/mets BC
Checkmark Data
Jun 2010 - Jun 2010: Data
Completed
1/2
67
US, Canada, Europe
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, trastuzumab-DM1, trastuzumab-MCC-DM1, T-DM1, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg, Perjeta
Hoffmann-La Roche, Roche Pharma AG
Metastatic Breast Cancer
08/11
08/11
NCT00951665: A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Checkmark Pooled P1 data
Dec 2011 - Dec 2011: Pooled P1 data
Completed
1/2
107
US
paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
Genentech, Inc.
Metastatic Breast Cancer
02/12
06/13
NCT00934856 / 2009-010000-28: A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Checkmark Pooled P1 data
Dec 2011 - Dec 2011: Pooled P1 data
Completed
1/2
98
US, Europe
Docetaxel, Pertuzumab, Trastuzumab emtansine, T-DM1
Hoffmann-La Roche
Breast Cancer
10/13
10/13
NCT02070094: Ado-Trastuzumab Emtansine(T-DM1) + ABT-737 in Treating Patients With HER2(+) Breast Cancer

Withdrawn
1/2
0
RoW
ado -trastuzumab emtansine T-DM1, Kadcyla, T-DM1, trastuzumab-DM1, trastuzumab-MCC-DM1 antibody-drug conjugate, Bcl-2 inhibitor ABT-737, ABT-737
Ukrainian Antitumor Center
Breast Cancer
03/14
09/15
2008-008276-14: A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanced or metastatic breast cancer who have progressed while receiving prior therapy

 
1/2
20
Europe
trastuzumab-MCC-DM1 (TDM-1), pertuzumab (rhuMAb 2C4), RO5304020/F02-01, RO4368451/F01,
F. Hoffmann-la Roche Ltd, F. Hoffmann-La Roche Ltd
Treatment in patients with HER2-overexpressing locally advanced or metastatic breast cancer
 
08/11
NCT02318901: Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer

Terminated
1/2
16
US
Pembrolizumab, KEYTRUDA, Trastuzumab, Herceptin, ado-trastuzumab emtansine, Kadcyla, Cetuximab, Erbitux
Western Regional Medical Center
Advanced Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
08/18
08/18
NCT02658084: Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Terminated
1/2
2
US
Vinorelbine, Vinorelbine tartrate, Navelbine, Trastuzumab Emtansine, Kadcyla, T-DM1, Trastuzumab-MCC-DM1
University of Miami, Genentech, Inc.
Breast Cancer, Metastatic Breast Cancer
10/18
10/18
NCT03709082: Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Terminated
1/2
3
US
Palbociclib 75mg, Ibrance, Letrozole 2.5mg, Femara, T-DM1, Ado-trastuzumab Emtansine, Kadcyla, Palbociclib 100mg, Palbociclib 125mg, Palbociclib
University of Kansas Medical Center, Pfizer
HER2-positive Breast Cancer, Breast Cancer Metastatic
03/20
02/21
NCT02657343: An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Completed
1/2
25
US
Ribociclib, LEE-011, T-DM1, Kadcyla, Trastuzumab, Herceptin, Fulvestrant, Faslodex
Dana-Farber Cancer Institute, Novartis
Breast Cancer
08/20
06/22
NSABP FB-10, NCT02236000: A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Checkmark neratinib + Kadycla in metastatic HER2+ breast cancer
Jun 2018 - Jun 2018: neratinib + Kadycla in metastatic HER2+ breast cancer
Checkmark In combination with Nerlynx in HER-2+ metastatic breast cancer
May 2018 - May 2018: In combination with Nerlynx in HER-2+ metastatic breast cancer
Checkmark NSABP-FB10 trial in In metastatic HER2+ breast cancer at AACR 2017
More
Completed
1/2
49
US
Neratinib, T-DM1
NSABP Foundation Inc, Puma Biotechnology, Inc.
Breast Cancer
12/20
08/21
NCT04298918 / 2019-004200-35: A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Terminated
1/2
1
RoW
Placebo, Venetoclax, Venclexta, Trastuzumab emtansine, Kadcyla
Hoffmann-La Roche
Breast Cancer
02/21
02/21
NCT03190967: T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Terminated
1/2
12
US
T-DM1, Ado-trastuzumab, TMZ, Temozolomide
National Cancer Institute (NCI)
Breast Cancer, Brain Metastasis, Brain Cancer
06/21
06/23
NCT05593094: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Active, not recruiting
1/2
210
Europe, US, RoW
ZN-A-1041, ZN-A-1041 Enteric Capsules, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c
Hoffmann-La Roche
Advanced Solid Tumors, HER2-positive Breast Cancer
07/26
07/26
Beamion BCGC-1, NCT06324357: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Recruiting
1/2
768
Europe, Japan, US, RoW
Zongertinib, BI 1810631, Hernexeos®, Trastuzumab deruxtecan, T-DXd; Enhertu®, Trastuzumab emtansine, T-DM1; Kadcyla®, Trastuzumab, Capecitabine, mFOLFOX6, zanidatamab
Boehringer Ingelheim
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
01/29
01/29
IL Believe, NCT05081609 / 2022-001191-34: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1/2
345
Europe, Canada, US, RoW
TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
Ascendis Pharma Oncology Division A/S, Ascendis Pharma Oncology Division A/S
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
08/27
08/29
AFT-50 EndoMAP, NCT04486352: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting
1/2
148
US
Atezolizumab - 28 Day Cycle, Tecentriq, L01XC32, Bevacizumab, Avastin, L01XC07, Ipatasertib, RG7440, GDC-0068, Talazoparib, Talzenna, L01XX60, Trastuzumab emtansine, T-DM1, Kadcyla, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, GDC-0077, Letrozole, Femara, Giredestrant, GDC-9545, Abemaciclib, Verzenio
Alliance Foundation Trials, LLC., Genentech, Inc., Foundation Medicine, Pfizer, Eli Lilly and Company
Endometrial Cancer
10/26
10/27

Download Options